Sera Prognostics, Inc. (SERA)

Market Cap	74.76M -48.4%
Revenue (ttm)	95,000 +1.1%
Net Income	-32.63M
EPS	-0.75
Shares Out	39.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,138
Open	2.010
Previous Close	2.010
Day's Range	1.841 - 2.139
52-Week Range	1.370 - 4.200
Beta	1.02
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 18, 2026

About SERA

Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction pane...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: SERA
• Website: https://www.sera.com

Financial Performance

In 2024, Sera Prognostics's revenue was $77,000, a decrease of -74.84% compared to the previous year's $306,000. Losses were -$32.90 million, -9.23% less than in 2023.